GNRH1 and prostate cancer: The authors concluded that in patients with prostate cancer with high metastatic risk, immediate androgen suppression with an GnRH analogue given during and for 3 years after external irradiation improves 10-year disease-free and overall survival without increasing late cardiovascular toxicity.